LifeVantage (Nasdaq: LFVN) Q3 revenue drops 25% as GLP-1 sales slow
Rhea-AI Filing Summary
LifeVantage Corporation reported weaker results for the third fiscal quarter ended March 31, 2026. Revenue was $43.7 million, down 25.2% from $58.4 million a year earlier, driven mainly by lower sales of the MindBody GLP-1 System, partly offset by the LoveBiome acquisition.
Gross margin remained high at 79.0%, but operating income declined to $1.7 million from $4.1 million. Net income fell to $1.4 million or $0.11 per diluted share, versus $3.5 million or $0.26. Adjusted EBITDA decreased to $3.2 million from $6.4 million.
Active accounts dropped to 109,000, down 22.1% year over year, reflecting fewer consultants and customers. The company generated $5.5 million of operating cash flow in the first nine months, held $12.5 million in cash with no debt, and raised its quarterly dividend to $0.05 per share, up 11.1%. Management now expects full-year fiscal 2026 revenue, adjusted EBITDA and adjusted EPS to be near the lower end of its prior guidance range.
Positive
- None.
Negative
- Sharp revenue and earnings decline: Q3 fiscal 2026 revenue fell 25.2% year over year to $43.7 million, with net income dropping to $1.4 million ($0.11 diluted EPS) from $3.5 million ($0.26), signaling materially weaker performance versus the prior-year quarter.
Insights
Revenue and earnings declined sharply, but margins, cash and dividends offer some support.
LifeVantage posted a $43.7M quarter, a 25.2% year-over-year revenue decline, mainly from weaker MindBody GLP-1 System sales. Operating income dropped to $1.7M and GAAP diluted EPS fell to $0.11, less than half the prior year level.
Despite pressure on the top line, gross margin stayed high at 79.0%, and Non-GAAP Adjusted EBITDA of $3.2M shows the business remains profitable on an adjusted basis. Cash and cash equivalents were $12.5M with no debt as of March 31, 2026, giving the company balance sheet flexibility.
Active accounts declined 22.1% to 109,000, which may affect future sales if not stabilized. Management now expects full-year fiscal 2026 results to be near the low end of its guidance range, while still increasing the quarterly dividend to $0.05 per share. Subsequent filings and updates will clarify whether new products and international expansion can offset GLP‑1-related headwinds.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
non-GAAP Net Income financial
MindBody GLP-1 System medical
earnout financial
Active Independent Consultants financial
nutrigenomics technical
Earnings Snapshot
For fiscal 2026, the company anticipates revenue, adjusted EBITDA and adjusted earnings per share to be close to the lower end of its previously issued guidance range.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 6, 2026, the Company issued a press release announcing its financial results for the three and nine months ended March 31, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit No. |
|
Description |
|||||||||
99.1 |
|
|
Press Release issued by the Company on May 6, 2026, announcing its financial results for the three and nine months ended March 31, 2026. |
||||||||
104 |
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
LIFEVANTAGE CORPORATION |
|
|
|
|
Date: |
May 6, 2026 |
By: |
/s/ Carl A. Aure |
|
|
|
Name: Carl A. Aure |
Exhibit 99.1
LifeVantage Announces Financial Results for the
Third Quarter of Fiscal 2026
Salt Lake City, UT, May 6, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2026.
Third Quarter Fiscal 2026 Summary*:
* All comparisons are on a year over year basis and compare the third quarter of fiscal 2026 to the third quarter of fiscal 2025, unless otherwise noted.
"Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 SystemÒ were only partially offset by the addition of LoveBiome," said Michael Beindorff, Interim CEO of LifeVantage. "Despite top-line headwinds, we remained focused on managing expenses and allocating capital, enabling us to continue repurchasing shares while maintaining a strong balance sheet and cash position. That said, we are not satisfied with our performance and are laser focused on making the changes necessary to improve results going forward. With our science-backed approach to nutrigenomics, diversified product portfolio, passionate consultant community, and strong financial foundation, LifeVantage is in a compelling position in the rapidly expanding health and wellness market with significant growth potential ahead, and we intend to realize that potential."
Third Quarter Fiscal 2026 Results
For the third quarter ended March 31, 2026, the Company reported revenue of $43.7 million, a 25.2% decrease compared to revenue of $58.4 million in the third quarter of fiscal 2025. Revenue in the Americas region for the third quarter of fiscal 2026 decreased 28.9% primarily due to declines in sales of the MindBody GLP-1 SystemÒ, partially offset by sales of LoveBiome, which the Company acquired in October 2025. Revenue in the Asia/Pacific & Europe region decreased 7.7%; on a constant currency basis, revenue in the Asia/Pacific & Europe region decreased approximately 8.9%.
Gross profit for the third quarter of fiscal 2026 was $34.5 million, or 79.0% of revenue, compared to $47.3 million, or 81.0% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 SystemÒ, along with increases in shipping and warehouse related expenses. Adjusted for the allowance for inventory obsolescence, non-GAAP gross profit was $34.7 million, or 79.4% of revenue.
Commissions and incentives expense for the third quarter of fiscal 2026 was $19.0 million, or 43.5% of revenue, compared to $26.2 million, or 44.8% of revenue, for the same period in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year period is primarily due to the timing
and magnitude of promotional and incentive programs and changes to the mix of customers and independent consultants in our overall Active Accounts.
Selling, general and administrative (SG&A) expense for the third quarter of fiscal 2026 was $13.9 million, or 31.7% of revenue, compared to $17.1 million, or 29.2% of revenue, for the same period in fiscal 2025. The increase in SG&A expenses as a percentage of revenue was primarily due to the overall decrease in sales volume.
Operating income for the third quarter of fiscal 2026 was $1.7 million compared to $4.1 million for the third quarter of fiscal 2025. Adjusted non-GAAP operating income for the third quarter of fiscal 2026 was $1.8 million compared to adjusted non-GAAP operating income of $4.1 million for the third quarter of fiscal 2025.
Net income for the third quarter of fiscal 2026 was $1.4 million, or $0.11 per diluted share, compared to $3.5 million, or $0.26 per diluted share for the third quarter of fiscal 2025. Adjusted non-GAAP net income for the third quarter of fiscal 2026 was $1.5 million, or $0.12 per diluted share, compared to adjusted non-GAAP income of $3.5 million, or $0.26 per diluted share, for the third quarter of fiscal 2025.
Adjusted EBITDA was $3.2 million for the third quarter of fiscal 2026, versus $6.4 million for the comparable period in fiscal 2025.
Balance Sheet & Liquidity
The Company generated $5.5 million of cash from operations during the first nine months of fiscal 2026 compared to $10.8 million in the same period in fiscal 2025. The Company's cash and cash equivalents at March 31, 2026 were $12.5 million, compared to $20.2 million at June 30, 2025, and there was no debt outstanding.
Share Repurchase
During the first nine months of fiscal 2026, the Company repurchased approximately 250,000 of its common shares for an aggregate price of approximately $1.6 million. As of March 31st, there was $59.0 million remaining under the $60 million share repurchase program approved by the Company’s Board of Directors in January.
Dividend Announcement
Today the Company announced the declaration of a cash dividend of $0.05 per common share, an 11.1% increase from the previous quarterly dividend of $0.045 per common share. The dividend will be paid on June 15, 2026 to all stockholders of record at the close of business on June 1, 2026.
Fiscal Year 2026 Guidance
The Company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnings per share to be close to the lower end of our previously issued guidance range. The Company expects a full year tax rate of approximately 18% to 20%. This guidance reflects the current trends in the business and the Company's strategic initiatives, including international expansion and new product launches. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2026.
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, May 20, 2026, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13759699, or (412) 317-6671 from international locations, and entering confirmation code 13759699.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations. The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 SystemÒ, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Cautionary Note Regarding Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, expected financial performance, including revenue margins, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.
Investor Relations Contacts:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
LIFEVANTAGE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED BALANCE SHEETS |
(Unaudited) |
|
|
March 31, 2026 |
|
|
June 30, 2025 |
|
||
(In thousands, except per share data) |
|
|
|
|
|
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
12,483 |
|
|
$ |
20,201 |
|
Accounts receivable |
|
|
2,420 |
|
|
|
3,294 |
|
Income tax receivable |
|
|
2,200 |
|
|
|
635 |
|
Inventory, net |
|
|
18,382 |
|
|
|
20,669 |
|
Prepaid expenses and other |
|
|
3,829 |
|
|
|
6,095 |
|
Total current assets |
|
|
39,314 |
|
|
|
50,894 |
|
Property and equipment, net |
|
|
6,850 |
|
|
|
6,207 |
|
Right-of-use assets |
|
|
6,908 |
|
|
|
8,041 |
|
Intangible assets, net |
|
|
3,187 |
|
|
|
245 |
|
Goodwill |
|
|
472 |
|
|
|
— |
|
Deferred income tax asset |
|
|
4,805 |
|
|
|
5,970 |
|
Other long-term assets |
|
|
591 |
|
|
|
601 |
|
TOTAL ASSETS |
|
$ |
62,127 |
|
|
$ |
71,958 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
5,147 |
|
|
$ |
4,600 |
|
Commissions payable |
|
|
5,948 |
|
|
|
7,237 |
|
Lease liabilities |
|
|
1,885 |
|
|
|
1,867 |
|
Other accrued expenses |
|
|
7,121 |
|
|
|
13,513 |
|
Total current liabilities |
|
|
20,101 |
|
|
|
27,217 |
|
Long-term lease liabilities |
|
|
8,321 |
|
|
|
9,811 |
|
Other long-term liabilities |
|
|
366 |
|
|
|
289 |
|
Total liabilities |
|
|
28,788 |
|
|
|
37,317 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ equity |
|
|
|
|
|
|
||
Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding |
|
|
— |
|
|
|
— |
|
Common stock — par value $0.0001 per share, 40,000 shares authorized and 12,609 and 12,429 issued and outstanding as of March 31, 2026 and June 30, 2025, respectively |
|
|
1 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
138,726 |
|
|
|
139,962 |
|
Accumulated deficit |
|
|
(103,656 |
) |
|
|
(104,147 |
) |
Accumulated other comprehensive loss |
|
|
(1,732 |
) |
|
|
(1,175 |
) |
Total stockholders’ equity |
|
|
33,339 |
|
|
|
34,641 |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
62,127 |
|
|
$ |
71,958 |
|
LIFEVANTAGE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF OPERATIONS |
(Unaudited) |
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
(In thousands, except per share data) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenue, net |
|
$ |
43,716 |
|
|
$ |
58,440 |
|
|
$ |
140,209 |
|
|
$ |
173,416 |
|
Cost of sales |
|
|
9,172 |
|
|
|
11,113 |
|
|
|
31,639 |
|
|
|
33,799 |
|
Gross profit |
|
|
34,544 |
|
|
|
47,327 |
|
|
|
108,570 |
|
|
|
139,617 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Commissions and incentives |
|
|
19,001 |
|
|
|
26,208 |
|
|
|
59,591 |
|
|
|
79,038 |
|
Selling, general and administrative |
|
|
13,865 |
|
|
|
17,066 |
|
|
|
44,546 |
|
|
|
50,528 |
|
Total operating expenses |
|
|
32,866 |
|
|
|
43,274 |
|
|
|
104,137 |
|
|
|
129,566 |
|
Operating income |
|
|
1,678 |
|
|
|
4,053 |
|
|
|
4,433 |
|
|
|
10,051 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income, net |
|
|
24 |
|
|
|
131 |
|
|
|
131 |
|
|
|
320 |
|
Other expense, net |
|
|
(46 |
) |
|
|
(4 |
) |
|
|
(194 |
) |
|
|
(524 |
) |
Total other income (expense) |
|
|
(22 |
) |
|
|
127 |
|
|
|
(63 |
) |
|
|
(204 |
) |
Income before income taxes |
|
|
1,656 |
|
|
|
4,180 |
|
|
|
4,370 |
|
|
|
9,847 |
|
Income tax expense |
|
|
(294 |
) |
|
|
(710 |
) |
|
|
(577 |
) |
|
|
(2,001 |
) |
Net income |
|
$ |
1,362 |
|
|
$ |
3,470 |
|
|
$ |
3,793 |
|
|
$ |
7,846 |
|
Net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
0.11 |
|
|
$ |
0.28 |
|
|
$ |
0.30 |
|
|
$ |
0.64 |
|
Diluted |
|
$ |
0.11 |
|
|
$ |
0.26 |
|
|
$ |
0.30 |
|
|
$ |
0.60 |
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
12,625 |
|
|
|
12,350 |
|
|
|
12,555 |
|
|
|
12,227 |
|
Diluted |
|
|
12,660 |
|
|
|
13,300 |
|
|
|
12,757 |
|
|
|
12,985 |
|
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Revenue by Region |
(Unaudited) |
|
|
Three Months Ended March 31, |
|
|
Nine Months Ended March 31, |
|
||||||||||||||||||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||||||||||||||
Americas |
|
$ |
34,268 |
|
|
|
78.4 |
% |
|
$ |
48,201 |
|
|
|
82.5 |
% |
|
$ |
110,006 |
|
|
|
78.5 |
% |
|
$ |
142,246 |
|
|
|
82.0 |
% |
Asia/Pacific & Europe |
|
|
9,448 |
|
|
|
21.6 |
% |
|
|
10,239 |
|
|
|
17.5 |
% |
|
|
30,203 |
|
|
|
21.5 |
% |
|
|
31,170 |
|
|
|
18.0 |
% |
Total |
|
$ |
43,716 |
|
|
|
100.0 |
% |
|
$ |
58,440 |
|
|
|
100.0 |
% |
|
$ |
140,209 |
|
|
|
100.0 |
% |
|
$ |
173,416 |
|
|
|
100.0 |
% |
Active Accounts |
(Unaudited) |
|
|
As of March 31, |
|
|
Change |
|
|
Percent |
|
|||||||||||||||
|
|
2026 |
|
|
2025 |
|
|
Year |
|
|
Change |
|
||||||||||||
Active Independent Consultants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Americas |
|
|
30,000 |
|
|
|
66.7 |
% |
|
|
35,000 |
|
|
|
67.3 |
% |
|
|
(5,000 |
) |
|
|
(14.3 |
)% |
Asia/Pacific & Europe |
|
|
15,000 |
|
|
|
33.3 |
% |
|
|
17,000 |
|
|
|
32.7 |
% |
|
|
(2,000 |
) |
|
|
(11.8 |
)% |
Total Active Independent Consultants |
|
|
45,000 |
|
|
|
100.0 |
% |
|
|
52,000 |
|
|
|
100.0 |
% |
|
|
(7,000 |
) |
|
|
(13.5 |
)% |
Active Customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Americas |
|
|
51,000 |
|
|
|
79.7 |
% |
|
|
74,000 |
|
|
|
84.1 |
% |
|
|
(23,000 |
) |
|
|
(31.1 |
)% |
Asia/Pacific & Europe |
|
|
13,000 |
|
|
|
20.3 |
% |
|
|
14,000 |
|
|
|
15.9 |
% |
|
|
(1,000 |
) |
|
|
(7.1 |
)% |
Total Active Customers |
|
|
64,000 |
|
|
|
100.0 |
% |
|
|
88,000 |
|
|
|
100.0 |
% |
|
|
(24,000 |
) |
|
|
(27.3 |
)% |
Active Accounts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Americas |
|
|
81,000 |
|
|
|
74.3 |
% |
|
|
109,000 |
|
|
|
77.9 |
% |
|
|
(28,000 |
) |
|
|
(25.7 |
)% |
Asia/Pacific & Europe |
|
|
28,000 |
|
|
|
25.7 |
% |
|
|
31,000 |
|
|
|
22.1 |
% |
|
|
(3,000 |
) |
|
|
(9.7 |
)% |
Total Active Accounts |
|
|
109,000 |
|
|
|
100.0 |
% |
|
|
140,000 |
|
|
|
100.0 |
% |
|
|
(31,000 |
) |
|
|
(22.1 |
)% |
(1) Active Independent Consultants have purchased product in the prior three months for retail or personal consumption. |
|
|
|
||||||
(2) Active Customers have purchased product in the prior three months for personal consumption only. |
|
|
|
||||||
(3) Total Active Accounts is the sum of Active Independent Consultant accounts and Active Customer accounts. |
|
|
|
|
|
|
|
|
|
LIFEVANTAGE CORPORATION AND SUBSIDIARIES |
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA |
(Unaudited) |
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
(In thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP Net Income |
|
$ |
1,362 |
|
|
$ |
3,470 |
|
|
$ |
3,793 |
|
|
$ |
7,846 |
|
Interest income, net |
|
|
(24 |
) |
|
|
(131 |
) |
|
|
(131 |
) |
|
|
(320 |
) |
Provision for income taxes |
|
|
294 |
|
|
|
710 |
|
|
|
577 |
|
|
|
2,001 |
|
Depreciation and amortization |
|
|
714 |
|
|
|
802 |
|
|
|
2,076 |
|
|
|
2,406 |
|
Non-GAAP EBITDA |
|
|
2,346 |
|
|
|
4,851 |
|
|
|
6,315 |
|
|
|
11,933 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Stock compensation expense |
|
|
704 |
|
|
|
1,522 |
|
|
|
2,083 |
|
|
|
4,160 |
|
Other expense, net |
|
|
46 |
|
|
|
4 |
|
|
|
194 |
|
|
|
524 |
|
Other adjustments(1) |
|
|
85 |
|
|
|
51 |
|
|
|
2,390 |
|
|
|
713 |
|
Total adjustments |
|
|
835 |
|
|
|
1,577 |
|
|
|
4,667 |
|
|
|
5,397 |
|
Non-GAAP Adjusted EBITDA |
|
$ |
3,181 |
|
|
$ |
6,428 |
|
|
$ |
10,982 |
|
|
$ |
17,330 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(1) Other adjustments breakout: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
MB System allowance for inventory obsolescence |
|
|
183 |
|
|
|
— |
|
|
|
2,551 |
|
|
|
— |
|
LoveBiome acquisition costs |
|
|
— |
|
|
|
— |
|
|
|
201 |
|
|
|
— |
|
Change in fair value of earnout |
|
|
(100 |
) |
|
|
— |
|
|
|
(400 |
) |
|
|
— |
|
Key management severance expenses |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
188 |
|
Executive team recruiting and transition expenses |
|
|
— |
|
|
|
51 |
|
|
|
— |
|
|
|
525 |
|
Other nonrecurring expenses, net of credits |
|
|
2 |
|
|
|
— |
|
|
|
38 |
|
|
|
— |
|
Total adjustments |
|
$ |
85 |
|
|
$ |
51 |
|
|
$ |
2,390 |
|
|
$ |
713 |
|
LIFEVANTAGE CORPORATION AND SUBSIDIARIES |
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS |
(Unaudited) |
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
(In thousands, except per share data) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP Net Income |
|
$ |
1,362 |
|
|
$ |
3,470 |
|
|
$ |
3,793 |
|
|
$ |
7,846 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
MB System allowance for inventory obsolescence |
|
|
183 |
|
|
|
— |
|
|
|
2,551 |
|
|
|
— |
|
LoveBiome acquisition costs |
|
|
— |
|
|
|
— |
|
|
|
201 |
|
|
|
— |
|
Change in fair value of earnout |
|
|
(100 |
) |
|
|
— |
|
|
|
(400 |
) |
|
|
— |
|
Key management severance expenses |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
188 |
|
Executive team recruiting and transition expenses |
|
|
— |
|
|
|
51 |
|
|
|
— |
|
|
|
525 |
|
Other nonrecurring expenses, net of credits |
|
|
2 |
|
|
|
— |
|
|
|
38 |
|
|
|
— |
|
Tax impact of adjustments(1) |
|
|
100 |
|
|
|
(11 |
) |
|
|
(430 |
) |
|
|
(164 |
) |
Total adjustments, net of tax |
|
|
185 |
|
|
|
40 |
|
|
|
1,960 |
|
|
|
549 |
|
Non-GAAP Net income: |
|
$ |
1,547 |
|
|
$ |
3,510 |
|
|
$ |
5,753 |
|
|
$ |
8,395 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
March 31, 2026 |
|
|
June 30, 2025 |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Diluted earnings per share, as reported |
|
$ |
0.11 |
|
|
$ |
0.26 |
|
|
$ |
0.30 |
|
|
$ |
0.60 |
|
Total adjustments, net of tax |
|
|
0.01 |
|
|
|
0.00 |
|
|
|
0.15 |
|
|
|
0.04 |
|
Diluted earnings per share, as adjusted(2) |
|
$ |
0.12 |
|
|
$ |
0.26 |
|
|
$ |
0.45 |
|
|
$ |
0.65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(1) Tax impact is based on the estimated annual tax rate for the years ended June 30, 2026 and 2025, respectively. |
|
|||||||||||||||
(2) May not add due to rounding. |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit |
(Unaudited) |
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
(In thousands, except percentage data) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenue, net |
|
$ |
43,716 |
|
|
$ |
58,440 |
|
|
$ |
140,209 |
|
|
$ |
173,416 |
|
Cost of sales |
|
|
9,172 |
|
|
|
11,113 |
|
|
|
31,639 |
|
|
|
33,799 |
|
GAAP Gross profit |
|
|
34,544 |
|
|
|
47,327 |
|
|
|
108,570 |
|
|
|
139,617 |
|
GAAP Gross profit percentage |
|
|
79.0 |
% |
|
|
81.0 |
% |
|
|
77.4 |
% |
|
|
80.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
MindBody GLP-1 System™ allowance for inventory obsolescence |
|
|
183 |
|
|
|
— |
|
|
|
2,551 |
|
|
|
— |
|
GAAP Gross profit |
|
|
34,727 |
|
|
|
47,327 |
|
|
|
111,121 |
|
|
|
139,617 |
|
GAAP Gross profit percentage |
|
|
79.4 |
% |
|
|
81.0 |
% |
|
|
79.3 |
% |
|
|
80.5 |
% |